Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

COVID-19 and Duchenne

With the growing concerns regarding COVID-19 (“coronavirus”) across Canadian communities and the world, our hearts go out to all those who've been impacted. We also want to show our profound gratitude to the health care professionals and everyone on the front lines of this pandemic. Jesse's Journey is here to support the Duchenne community during [...]

Jesse’s Journey: 2019/20 Research Grants Announced

Since 1995, Jesse’s Journey has strongly believed in strong partnerships with academics and clinicians to fund the most promising research for Duchenne muscular dystrophy. This focus and fundraising effort have brought us to granting more than $13.1 million across 45 research projects. We have attracted applications from leading Duchenne researchers from all over the world including the […]


Sarepta Therapeutics: Positive Safety and Efficacy Data from SRP-9001

Sarepta Therapeutics has announced positive results from their gene therapy, SRP-9001, under investigation for Duchenne muscular dystrophy. Preliminary data based upon four boys demonstrated the therapy to be safe and tolerable at one year in their clinical trial. Results were published in JAMA Neurology and further support the potential for SRP-9001 to provide clinically meaningful […]


Nippon Shinyaku: Viltolarsen Update

The European Commission has granted orphan drug designation to viltolarsen, a treatment for people with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. See the June 8, 2020, vilolarsen press release here. This compound was approved in Japan in March this year under the brand name Viltepso and is currently under priority review by the FDA in the USA. It […]


Jesse’s Journey: $1M Grant Towards Clinical Trial

Jesse's Journey grants $1M toward the launch of a clinical trial investigating vamolorone for Duchenne muscular dystrophy in Canada. Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, is proud to announce a $1M grant towards a clinical trial evaluating vamorolone for the first time in children 2-4 years of age prior to the [...]

Santhera Pharmaceuticals: New licensing agreement with ReveraGen Pharma

On September 2, 2020, Santhera announced their new licensing agreement with ReveraGen Pharma, the company up until now, responsible for vamorolone. This agreement offers Santhera the advantage of full control of vamorolone. It allows them to pursue the development, registration, and commercialization of this anti-inflammatory drug candidate more effectively and efficiently. Santhera remains committed to […]


NS Pharma: FDA grants accelerated approval for Viltepso (viltolarsen)

The FDA has granted accelerated approval for Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene is amenable to exon 53 skipping. Click here to read the full press release. The early clinical data demonstrated an increase in dystrophin production that is reasonably […]


Jesse’s Journey: Brand Awareness Survey

As Jesse’s Journey moves forward with future marketing and communication initiatives, we want to know: What does the Jesse’s Journey "brand" mean to you? We ask that you share your thoughts by completing a short survey - only about 10 minutes -  which will help provide us with insights and direction that will enhance our [...]

Jesse’s Journey + Muscular Dystrophy Canada (MDC): Return to School Webinar

Jesse's Journey and Muscular Dystrophy Canada (MDC) were very pleased to join forces to share information on returning to school for children with neuromuscular disorders. Many parents, caregivers, and guardians face new and difficult choices about how their child will return to school in the fall, such as deciding between in-person, virtual learning and home [...]

Congratulations: Dr. Rudnicki Elected as Fellow of the Royal Society

Jesse’s Journey would like to congratulate Dr. Michael Rudnicki, Chief Scientific Officer of Satellos Bioscience and a Jesse’s Journey research funding recipient, for being elected as a Fellow of the Royal Society, the United Kingdom’s national academy of sciences. The Royal Society is the world’s oldest and most esteemed scientific institution founded in 1660 and […]


Solid Biosciences: Update on SGT-001 Phase 1/2 Clinical Trial

On July 24, 2020, Solid Biosciences announced an update on their phase 1/2 clinical trial on SGT-001, an investigational gene therapy under development for Duchenne. This trial is currently on hold due to some safety concerns, but patients enrolled are continuing to engage in study-related activities. Their clinical biomarker results presented at a recent scientific […]


Catabasis Connection: July 2020

Catabasis has provided an update on their “North Star Ambulatory Assessment in Duchenne Muscular Dystrophy” as presented at the Parent Project Muscular Dystrophy (PPMD) Conference in July 2020. Click here to see the July 2020 – Catabasis Connection Edasalonexent: In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key […]


PTC Therapeutics: Translarna (Ataluren) Update

PTC Therapeutics announced the expansion of its European label for translarna (ataluren). Ataluren restores dystrophin production in individuals with Duchenne caused by a nonsense mutation. This treatment is only available in Europe. The label expansion now allows patients who have lost their ability to walk to continue to use ataluren. Read the full press release […]


Sarepta Therapeutics: Casimersen Update

Sarepta Therapeutics has completed a new drug submission to the FDA in the United States for Casimersen, their third exon-skipping medicine for individuals with Duchenne amenable to exon 45. Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne. Casimersen is the third exon-skipping medicine using the […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.